Working… Menu
Trial record 31 of 38 for:    cemiplimab

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03002376
Recruitment Status : Active, not recruiting
First Posted : December 23, 2016
Last Update Posted : June 20, 2019
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : March 5, 2019
Estimated Study Completion Date : October 22, 2019